From DIA
|
New at DIA: Solution Provider Webinars
DIA's Solution Provider Webinars offer FREE access to
cutting-edge information presented by some of the industry's leading experts,
right from the comfort of your home or office. Our first Solution Provider
Webinar will be brought to you by DIA in cooperation with ICON plc.
Oncology Clinical Trial Endpoints: Keys to Maximizing
Success in Your Development Programs
March 11 | 11:00 AM-12:30 PM EST
The high cost of drug development is partly due to the high
rates of failure. Understanding why some trials of promising products do not
succeed makes it more likely that your next trial will avoid the pitfalls. In
this FREE webinar you will learn the strategies needed to improve your
cancer development programs and discuss how the implementation of better
trial design and medical imaging data provide early indicators on future drug
success.
Featured topics:
• Why are Oncology Clinical Trial Success Rates so Low? • Challenges and Strategies to Improve Cancer Drug Development • Medical Imaging in Oncology Trials: How do we get From Images to Endpoints? • New Strategies for Improving Early Stage Cancer Drug Development
Presenters:
Samuel C. Blackman, MD, PhD Executive Director, Head of Translational Medicine, Seattle Genetics, Inc., United States James J. Conklin, MD, MS Senior Vice President, Medical and Scientific Affairs, ICON Medical Imaging, United States
Jamal Gasmi, MD, PhD
Vice President and Global Leader, Oncology and Hematology Drug Development, ICON Clinical Research, France
Gregory V. Goldmacher, MD, PhD
Director, Medical and Scientific Affairs, Head of Oncology Imaging, ICON Medical Imaging, United States |
Social media enthusiast at the intersection of IT and Health care. Employee of The Drug Information Association: The Global Forum for Therapeutic Innovation & Regulatory Science - A Neutral, Nonprofit Association
Thursday, February 21, 2013
First of DIA's Solution Provider Webinars - Oncology Clinical Trial Endpoints - March 11
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment